BCL2 has long been associated with resistance to the standard cytarabine-based chemotherapy [16] and is the target of venetoclax, which is being investigated in multiple AML clinical trials (https://clinicaltrials.gov/search?cond=AML&intr=venetoclax (accessed on 29 September 2025)). Here, BCL2 is linked to acute myeloid leukemia.